David Pérol

12.4k total citations · 1 hit paper
256 papers, 6.1k citations indexed

About

David Pérol is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, David Pérol has authored 256 papers receiving a total of 6.1k indexed citations (citations by other indexed papers that have themselves been cited), including 131 papers in Pulmonary and Respiratory Medicine, 105 papers in Oncology and 47 papers in Cancer Research. Recurrent topics in David Pérol's work include Sarcoma Diagnosis and Treatment (47 papers), Gastrointestinal Tumor Research and Treatment (33 papers) and Cancer Genomics and Diagnostics (33 papers). David Pérol is often cited by papers focused on Sarcoma Diagnosis and Treatment (47 papers), Gastrointestinal Tumor Research and Treatment (33 papers) and Cancer Genomics and Diagnostics (33 papers). David Pérol collaborates with scholars based in France, United Kingdom and United States. David Pérol's co-authors include Jean‐Yves Blay, Sylvie Chabaud, Isabelle Ray‐Coquard, Christine Chevreau, Axel Le Cesne, Sylvie Négrier, Bernard Escudier, Florence Duffaud, C. Carrié and Alain Ravaud and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.

In The Last Decade

David Pérol

241 papers receiving 6.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas

2009 624 citations Isabelle Ray‐Coquard, Claire Cropet et al. profile →

Peers

Countries citing papers authored by David Pérol

Since Specialization

Citations

This map shows the geographic impact of David Pérol's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Pérol with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Pérol more than expected).

Fields of papers citing papers by David Pérol

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Pérol. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Pérol. The network helps show where David Pérol may publish in the future.

Co-authorship network of co-authors of David Pérol

This figure shows the co-authorship network connecting the top 25 collaborators of David Pérol. A scholar is included among the top collaborators of David Pérol based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Pérol. David Pérol is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Integrating Environmental Impact in Health Technology Assessment: An Exploratory Study 2025 ·PharmacoEconomics ·(unknown), Julien Péron, Matthieu Delaye, David Pérol, Isabelle Durand‐Zaleski, Max Piffoux	1
2	59MO COTESARC – A multicentre, phase I-II clinical trial evaluating the combination of MEK and PDL-1 inhibitors in patients (pts) with advanced soft tissue sarcoma (STS): Results from complex (CG) and simple genomic (SG) STS cohorts 2024 ·ESMO Open ·Armelle Dufresne, Mehdi Brahmi, Claire Cropet, Rastislav Bahleda, Sarah Watson, Patricia Pautier, (unknown), Isabelle Aerts, (unknown), Anne Sophie Defachelles, Benjamin Verret, (unknown), Cécile Guichard, (unknown), David Pérol, Jean‐Yves Blay, (unknown)	0
3	The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers 2024 ·Science Translational Medicine ·(unknown), Carlos Gomez‐Roca, Sylvie Chabaud, Céline Rodriguez, (unknown), (unknown), (unknown), (unknown), Isabelle Treilleux, Lauriane Eberst, C. Terret, (unknown), (unknown), David Pérol, Jean‐Pierre Delord, Christophe Caux, Bertrand Dubois, Christine Ménétrier‐Caux, Nathalie Bendriss‐Vermare, Philippe A. Cassier	32
4	LBA22 Connected device and therapeutic patient education to promote physical activity among in women with localized breast cancer: Results from the DISCO randomized trial 2023 ·Annals of Oncology ·Béatrice Fervers, (unknown), Thierry Durand, David Pérol, Camille Schiffler, (unknown), Lionel Perrier, Marie Préau, Thomas Bachelot, Pierre-Étienne Heudel, C. Faure, Mellie Heinemann, (unknown), (unknown), (unknown), (unknown), Julien Grenier, Olivier Trédan, Jean‐Yves Blay, Olivia Pérol	1
5	1684TiP PARPiPANC: A multicentric, single arm, phase II assessing niraparib as first line therapy for patients with metastatic homologous repair-deficient pancreatic cancer 2023 ·Annals of Oncology ·Philippe A. Cassier, Claire Cropet, Clélia Coutzac, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Marion Chauvenet, François Ghiringhelli, Gaël S. Roth, David Pérol	0
6	Intra-operative High-Intensity Focused Ultrasound in Patients With Colorectal Liver Metastases: A Prospective Ablate-and-Resect Study 2023 ·Ultrasound in Medicine & Biology ·Aurélien Dupré, Michel Rivoire, (unknown), Claire Cropet, (unknown), Patrice Peyrat, Yao Chen, David Pérol, David Melodelima	5
7	Long-term follow-up of nilotinib in patients with advanced tenosynovial giant cell tumours 2022 ·European Journal of Cancer ·(unknown), Peter Grimison, Christine Chevreau, Silvia Stacchiotti, Sophie Piperno‐Neumann, Axel Le Cesne, Virginia Ferraresi, Antoîne Italiano, Florence Duffaud, Nicolas Penel, (unknown), Sylvie Chabaud, L. van der Heijden, David Pérol, Michiel A. J. van de Sande, Jean‐Yves Blay, Hans Gelderblom	17
8	Survival and risk of COVID-19 after SARS-COV-2 vaccination in a series of 2391 cancer patients 2022 ·European Journal of Cancer ·Pierre-Étienne Heudel, Bertrand Favier, (unknown), Souad Assaad, (unknown), Olivier Trédan, Thomas Bachelot, I. L. Ray-Coquard, (unknown), (unknown), Bénédicte Mastroïanni, Virginie Avrillon, Anne‐Sophie Michallet, Philippe Zrounba, Sylvie Chabaud, David Pérol, Jean‐Yves Blay	13
9	Radioresistance and genomic alterations in head and neck squamous cell cancer: Sub‐analysis of the ProfiLER protocol 2021 ·Head & Neck ·(unknown), Nicolas Magné, Jérôme Fayette, Élisabeth Daguenet, S. Racadot, P. Pommier, Benoîte Méry, Alexis Vallard, Fabien Tinquaut, Eve‐Marie Neidhardt‐Berard, Philippe A. Cassier, Valéry Attignon, Daniel Pissaloux, Qing Wang, Emilie Sohier, David Pérol, Jean‐Yves Blay, Olivier Trédan	2
10	MEVITEM—a phase I/II trial of vismodegib + temozolomide vs temozolomide in patients with recurrent/refractory medulloblastoma with Sonic Hedgehog pathway activation 2021 ·Neuro-Oncology ·Didier Frappaz, Marc Barritault, (unknown), Florence Laigle–Donadey, Olivier Chinot, Émilie Le Rhun, Alice Bonneville-Levard, Andreas F. Hottinger, David Meyronnet, (unknown), Gwenaële Garin, David Pérol	21
11	Long term term follow-up of tyrosine kinase inhibitors treatments in inoperable or relapsing diffuse type tenosynovial giant cell tumors (dTGCT) 2020 ·PLoS ONE ·Mehdi Brahmi, Philippe A. Cassier, Armelle Dufresne, Sylvie Chabaud, Marie Karanian, Alexandra Meurgey, (unknown), F. Gouin, Gualter Vaz, Jérôme Garret, Marie‐Pierre Sunyach, Aurélien Dupré, Perrine Marec‐Bérard, Nadège Corradini, David Pérol, Isabelle Ray‐Coquard, Jean‐Yves Blay	9
12	Evaluation of the Feasibility, Safety, and Accuracy of an Intraoperative High-intensity Focused Ultrasound Device for Treating Liver Metastases 2019 ·Journal of Visualized Experiments ·Aurélien Dupré, David Melodelima, David Pérol, Yao Chen, (unknown), Jean‐Yves Chapelon, Michel Rivoire	4
13	A multicentric randomized phase II clinical trial evaluating high-dose thiotepa as adjuvant treatment to standard chemotherapy in patients with resectable relapsed osteosarcoma 2019 ·European Journal of Cancer ·Perrine Marec‐Bérard, Cécile Dalban, Nathalie Gaspar, Laurence Brugières, Jean‐Claude Gentet, Cyril Lervat, Nadège Corradini, Marie‐Pierre Castex, Claudine Schmitt, Hélène Pacquement, Marie‐Dominique Tabone, Mehdi Brahmi, (unknown), Jean‐Yves Blay, David Pérol	21
14	HEPATOFLUO: A prospective monocentric study assessing the benefits of indocyanine green (ICG) fluorescence for hepatic surgery 2018 ·Journal of Surgical Oncology ·Patrice Peyrat, Ellen Blanc, (unknown), (unknown), Céline Ferlay, David Pérol, (unknown), Michel Rivoire, Aurélien Dupré	20
15	A Personalized Physical Activity Program With Activity Trackers and a Mobile Phone App for Patients With Metastatic Breast Cancer: Protocol for a Single-Arm Feasibility Trial 2018 ·JMIR Research Protocols ·Lidia Delrieu, Olivia Pérol, Béatrice Fervers, Christine M. Friedenreich, Jeff K. Vallance, (unknown), David Pérol, Brice Canada, (unknown), Armelle Dufresne, Thomas Bachelot, Pierre-Étienne Heudel, Olivier Trédan, Marina Touillaud, Vincent Pialoux	20
16	Efficacy of high-intensity focused ultrasound-assisted hepatic resection (HIFU-AR) on blood loss reduction in patients with liver metastases requiring hepatectomy: study protocol for a randomized controlled trial 2017 ·Trials ·Aurélien Dupré, David Pérol, Ellen Blanc, Patrice Peyrat, (unknown), Yao Chen, (unknown), (unknown), David Melodelima, Michel Rivoire	11
17	Is There a Role for Pelvic Irradiation in Localized Prostate Adenocarcinoma: Final Results of the European Groupe d'Etude des Tumeurs Uro-Génitales (GETUG-01) Randomized Study 2015 ·International Journal of Radiation OncologyBiologyPhysics ·P. Pommier, Sylvie Chabaud, J. L. Lagrange, Pierre Richaud, É. Le Prisé, Jean-Philippe Wagner, (unknown), (unknown), Jean-Philippe Suchaud, V. Bernier, Muriel Habibian, David Pérol, C. Carrié	2
18	Cost Effectiveness of Pegfilgrastim Versus Filgrastim After High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients with Lymphoma and Myeloma 2013 ·Applied Health Economics and Health Policy ·Lionel Perrier, (unknown), David Pérol, Philippe Quittet, Aline Schmidt, (unknown), Christian de Peretti, Bertrand Favier, Pierre Biron, Philippe Moreau, Jacques Olivier Bay, Séverine Lissandre, Fabrice Jardin, Daniel Espinouse, Catherine Sebban	8
19	Randomized, Phase III Study of Gemcitabine or Erlotinib Maintenance Therapy Versus Observation, With Predefined Second-Line Treatment, After Cisplatin-Gemcitabine Induction Chemotherapy in Advanced Non–Small-Cell Lung Cancer 2012 ·Journal of Clinical Oncology ·M. Pérol, C. Chouaïd, David Pérol, Fabrice Barlési, Radj Gervais, Virginie Westeel, Jacky Créquit, H. Léna, A. Vergnenègre, Gérard Zalcman, I. Monnet, H. Le Caer, P. Fournel, L. Falchero, M. Poudenx, F. Vaylet, Céline Ségura‐Ferlay, Mojgan Devouassoux‐Shisheboran, Miquel Tarón, B. Milleron	166
20	Prognostic value of serum CA9 in patients with metastatic clear cell renal cell carcinoma under targeted therapy. 2012 ·PubMed ·Marc Gigante, Guorong Li, Céline Ferlay, David Pérol, Ellen Blanc, Stéphane Paul, An Zhao, Jacques Tostain, Bernard Escudier, Sylvie Négrier, Christian Genin	21

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact